| Drug ID: | Drug110 |
|---|---|
| Drug Name: | Carotegrast methyl |
| CID: | 9872780 |
| DrugBank ID: | DB16119 |
| Modality: | Small Molecule |
| Groups: | NULL |
| US Approved: | NULL |
| Other Approved: | NULL |
| Identifier: | NCT03531892, , NCT06897150 |
| Molecular Formula: | C28H26Cl2N4O5 |
| Molecular Weight: | 569.4 g/mol |
| Isomeric SMILES: | CN1C2=C(C=C(C=C2)N(C)C)C(=O)N(C1=O)C3=CC=C(C=C3)C[C@@H](C(=O)OC)NC(=O)C4=C(C=CC=C4Cl)Cl |
| Synonyms: | Carotegrast methyl; 401905-67-7; AJM300; Carogra; UNII-OYK17DYO9M; OYK17DYO9M; Carotegrast methyl (JAN); CAROTEGRAST METHYL [JAN]; DTXSID60193189; Methyl (2S)-2-(2,6-dichlorobenzamido)-3-(4-(6-(dimethylamino)-1-methyl-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl)phenyl)propanoate |
| Phase 0: | 0 |
| Phase 1: | 0 |
| Phase 2: | 0 |
| Phase 3: | 0 |
| Phase 4: | 0 |
| Description: | NULL |
Molecular Structure
Knowledge Graph
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT06897150 | Carotegrast Methyl in Ulcerative Colitis | PHASE4 | COMPLETED | Takayuki Yamamoto | Ulcerative Colitis | DRUG: Carotegrast methyl | Details |
| NCT03531892 | A Study to Evaluate the Safety and Efficacy of AJM300 in Participants With Active Ulcerative Colitis | PHASE3 | COMPLETED | EA Pharma Co., Ltd. | Colitis, Ulcerative | DRUG: AJM300|DRUG: Placebo | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| No data available | |||||
[Pharmacological and Clinical data of oral alpha 4 integrin antagonist, Caroteg…
PMID: 36858506
Year: 2023
Relationship Type:
Treatment
Score: 9.5
Carotegrast-methyl (brand name: CAROGRA((R)) Tablets) is a new chemical entity created by Ajinomoto Pharmaceuticals Co., Ltd. (currently EA Pharma Co…
Carotegrast Methyl: First Approval
PMID: 35723803
Year: 2022
Relationship Type:
Treatment
Score: 7.5
Carotegrast methyl (Carogra((R))) is a small-molecule alpha4 integrin antagonist being developed by EA Pharma (formerly Ajinomoto Pharmaceuticals) an…
AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction th…
PMID: 35366419
Year: 2022
Relationship Type:
Treatment
Score: 7.5
BACKGROUND: AJM300 is an oral, small-molecule alpha4-integrin antagonist. We assessed the efficacy and safety of AJM300 in patients with moderately a…
Efficacy and safety of carotegrast methyl in active ulcerative colitis: a real-…
PMID: 40659338
Year: 2025
Relationship Type:
Treatment
Score: 6.5
BACKGROUND/AIMS: Carotegrast methyl, an oral alpha4-integrin inhibitor, was recently approved for the treatment of active ulcerative colitis (UC). Ho…